Acadia Pharmaceuticals (ACAD) shares surged 26.5% on Friday after the company announced that the U.S. District Court in Delaware had ruled in its favor concerning the ‘721 formulation patent for its lead drug, Nuplazid (pimavanserin). The Court upheld Acadia’s position on both infringement and validity in its patent litigation against Aurobindo Pharma Limited and other abbreviated new drug application filers.Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated wi ...